Deep Track Capital, LP has sold NKTR and made no open-market buys since May 2024

Deep Track Capital, LP is a Greenwich, Connecticut–based investment firm focused exclusively on the life sciences industry, including biotechnology, specialty pharmaceuticals, medical devices, diagnostics, and related tools and services.( Founded in 2020 by healthcare investor David Kroin, the firm manages several billion dollars in assets and develops long-term partnerships with management teams of innovative public and pre-IPO biotechnology companies.( Deep Track Capital typically invests in both publicly traded and select privately held companies, using structures such as common equity, private investment in public equity (PIPE) transactions, and other securities, and often seeks to lead transactions while building large investor syndicates.( As a corporate insider, Deep Track Capital, LP has held a significant ownership stake (around 10%) in Nektar Therapeutics (NKTR), reflecting its strategy of building sizable positions in life sciences businesses it believes have strong long-term potential.(

Operating from offices on Greenwich Avenue in Greenwich, Connecticut, Deep Track Capital positions itself as a sector-specialist institutional investor that contributes not only capital but also time, expertise, and access to its network to support portfolio company growth.( The firm’s leadership is anchored by founder David Kroin, who has more than 25 years of healthcare investment experience and previously co-founded Great Point Partners, where he helped manage biotechnology-focused hedge and private equity funds.( Deep Track Capital’s investment approach is fundamentally driven and research-intensive, aiming to capitalize on the diverse development and commercialization outcomes characteristic of the biotech and broader life sciences sector.(

Written by Perplexity from public sources.